<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076543</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2011-01456</org_study_id>
    <secondary_id>NCI-2011-01456</secondary_id>
    <secondary_id>09-443-A</secondary_id>
    <secondary_id>CDR0000666432</secondary_id>
    <secondary_id>8309</secondary_id>
    <secondary_id>8309</secondary_id>
    <secondary_id>N01CM00071</secondary_id>
    <secondary_id>N01CM62201</secondary_id>
    <secondary_id>P30CA014599</secondary_id>
    <nct_id>NCT01076543</nct_id>
  </id_info>
  <brief_title>Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma</brief_title>
  <official_title>Phase I/II Investigation of Temsirolimus Plus Lenalidomide in Relapsed Non-Hodgkin Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I/II trial studies the side effects and the best dose of lenalidomide when given
      together with temsirolimus and to see how well it works in treating patients with Hodgkin
      lymphoma or non-Hodgkin lymphoma that has come back after a period of improvement or is not
      responding to treatment. Biological therapies, such as lenalidomide, may stimulate the immune
      system in different ways and stop cancer cells from growing. Lenalidomide may also stop the
      growth of Hodgkin lymphoma or non-Hodgkin lymphoma by blocking blood flow to the cancer.
      Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for
      cell growth. Giving lenalidomide together with temsirolimus may kill more cancer cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the safety, toxicity, and maximum tolerated dose of lenalidomide when
      combined with temsirolimus in patients with relapsed lymphomas. (Phase I) II. To determine
      complete and overall response rate of lenalidomide plus temsirolimus in patients with
      relapsed lymphomas as stratified by histology: follicular lymphoma, diffuse large B-cell
      lymphoma, and lymphoma not otherwise specified (NOS) (including Hodgkin lymphoma, T-cell
      non-Hodgkin lymphoma [T-NHL], lymphoplasmacytic lymphoma, and mantle cell lymphoma). (Phase
      II) III. To determine duration of response, progression-free survival, and overall survival
      of lenalidomide plus temsirolimus in patients with relapsed lymphomas as stratified by
      histology: diffuse large B-cell lymphoma, follicular lymphoma, and lymphoma NOS (including
      Hodgkin lymphoma, T-NHL, lymphoplasmacytic lymphoma, mantle cell lymphoma). (Phase II)

      SECONDARY OBJECTIVES:

      I. To determine mammalian target of rapamycin (mTOR) pathway activation in pre-treatment
      tumor tissue.

      II. To determine angiogenic and microenvironmental status of pre-treatment tissue and
      peripheral blood samples, and to evaluate changes following treatment with temsirolimus and
      lenalidomide.

      III. To determine differentially expressed genes associated with differences in clinical
      response and in progression-free survival (PFS) in patients with diffuse large B-cell
      lymphoma (DLBCL) and follicular lymphoma (FL) (Groups A and B, respectively).

      IV. To determine a methylation signature predictive of clinical response and PFS in patients
      with DLBCL and FL (Groups A and B, respectively).

      OUTLINE: This is a phase I, dose-escalation study of lenalidomide followed by a phase II
      study.

      Patients receive lenalidomide orally (PO) on days 1-21 and temsirolimus intravenously (IV)
      over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in
      the absence of disease progression or unacceptable toxicity. Patients with stable disease
      after 2 courses may continue therapy for up to 52 weeks.

      After completion of study treatment, patients are followed up for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 15, 2010</start_date>
  <completion_date type="Actual">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose-limiting Toxicity (DLT), Phase I Patients Only</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of dose-limiting toxicity (DLT) defined as any grade 3 or 4 adverse events as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete Response (Phase II)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (Phase II)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) (Phase II)</measure>
    <time_frame>Time from study entry until disease progression or death from any cause, assessed up to 5 years</time_frame>
    <description>Kaplan-Meier curves will be generated for PFS stratified by histology; median PFS times will be determined and 90% confidence intervals derived as described in Brookmeyer and Crowley.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) (Phase II)</measure>
    <time_frame>Time from study entry until death from any cause, assessed up to 6 years</time_frame>
    <description>Kaplan-Meier curves will be generated for OS stratified by histology; median OS times will be determined and 90% confidence intervals derived as described in Brookmeyer and Crowley.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>AIDS-Related Hodgkin Lymphoma</condition>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <condition>Recurrent Follicular Lymphoma</condition>
  <condition>Recurrent Lymphoplasmacytic Lymphoma</condition>
  <condition>Recurrent Marginal Zone Lymphoma</condition>
  <condition>Recurrent Non-Hodgkin Lymphoma</condition>
  <condition>Recurrent T-Cell Non-Hodgkin Lymphoma</condition>
  <condition>Waldenstrom Macroglobulinemia</condition>
  <arm_group>
    <arm_group_label>Treatment (lenalidomide, temsirolimus)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive lenalidomide PO on days 1-21 and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients with stable disease after 2 courses may continue therapy for up to 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (lenalidomide, temsirolimus)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (lenalidomide, temsirolimus)</arm_group_label>
    <other_name>CC-5013</other_name>
    <other_name>CC5013</other_name>
    <other_name>CDC 501</other_name>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (lenalidomide, temsirolimus)</arm_group_label>
    <other_name>CCI-779</other_name>
    <other_name>CCI-779 Rapamycin Analog</other_name>
    <other_name>Cell Cycle Inhibitor 779</other_name>
    <other_name>Rapamycin Analog</other_name>
    <other_name>Rapamycin Analog CCI-779</other_name>
    <other_name>Torisel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histology: bone marrow biopsies (with the exception of lymphoplasmacytic lymphoma) as
             the sole means of diagnosis are not acceptable; fine needle aspirates are not
             acceptable

               -  Phase I: previously treated, histologically confirmed Hodgkin and non-Hodgkin
                  lymphomas; the only exception to a requirement for a lymph node biopsy is
                  lymphoplasmacytic lymphoma, which can be diagnosed based on morphologic evidence
                  in the bone marrow plus the appropriate paraprotein

               -  Phase II: previously treated, histologically confirmed mature non-Hodgkin
                  lymphoma (NHL) stratified by histology:

                    -  Group A: diffuse large B-cell lymphoma (NOTE: all patients with DLBCL must
                       have germinal center vs. non-germinal center phenotype established via
                       immunohistochemistry)

                    -  Group B: follicular lymphoma

                    -  Group C: lymphoma NOS (including Hodgkin lymphoma, T-NHL, marginal zone
                       lymphoma, lymphoplasmacytic

          -  No limit to number of prior therapies; prior autologous transplantation is allowed

          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2

          -  Absolute neutrophil count (ANC) &gt;= 1,000/uL

          -  Platelet count &gt;= 75,000/uL

          -  Total bilirubin =&lt; 1.5 times upper limit of normal (ULN) (unless due to Gilbert's)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt; 2.5 times ULN

          -  Creatinine clearance &gt;= 60 mL/min as determined by calculated Cockcroft-Gault equation

          -  Fasting serum cholesterol =&lt; 350 mg/dL

          -  Fasting serum triglycerides =&lt; 2.5 times ULN

          -  All patients are required to have measurable disease; non-measurable disease alone is
             not acceptable; any tumor mass &gt; 1 cm is acceptable; lesions that are considered
             non-measurable include the following:

               -  Bone lesions (lesions if present should be noted)

               -  Ascites

               -  Pleural/pericardial effusion

               -  Lymphangitis cutis/pulmonis

               -  Bone marrow (involvement by lymphoma should be noted)

               -  For Waldenstrom's macroglobulinemia, measurable disease is defined as at least
                  one lesion with a single diameter of greater than 2 cm by computed tomography or
                  bone marrow involvement with greater than 10% malignant cells and quantitative
                  monoclonal protein (immunoglobulin M [IgM], IgG, IgA) greater than 1,000 mg/dL

          -  Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy
             test with a sensitivity of at least 25 mIU/mL within 10 - 14 days and again within 24
             hours prior to starting cycle 1 of lenalidomide; further, they must either commit to
             continued abstinence from heterosexual intercourse or begin TWO acceptable methods of
             birth control: one highly effective method and one additional effective method AT THE
             SAME TIME, at least 28 days before starting lenalidomide; FCBP must also agree to
             ongoing pregnancy testing; men must agree to use a latex condom during sexual contact
             with a FCBP, even if they have had a successful vasectomy; a FCBP is a sexually mature
             woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has
             not been naturally postmenopausal for at least 24 consecutive months (i.e., has had
             menses at any time in the preceding 24 consecutive months); all patients must be
             counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal
             exposure

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Patients who are human immunodeficiency virus (HIV) positive are allowed to
             participate BUT must meet the following criteria:

               -  No acquired immune deficiency syndrome (AIDS)-defining illness, AND

               -  Cluster of differentiation (CD) 4 count &gt;= 400 cells/mm^3, AND

               -  No anti-retroviral therapy (including high-active antiretroviral therapy [HAART])
                  within 7 days of starting protocol therapy, AND

               -  Patient may not take concurrent anti-retroviral therapy (including HAART) while
                  on protocol

               -  NOTE: it is not generally recommended to suspend anti-retroviral therapy
                  (including HAART); the medical team enrolling a patient who suspends
                  anti-retroviral therapy for the purpose of study participation must have a
                  documented note reviewing the potential risks/benefits with the patient in the
                  medical chart

        Exclusion Criteria:

          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
             nitrosoureas or mitomycin C) prior to entering the study or those who have not
             recovered from adverse events due to agents administered more than 4 weeks earlier

          -  Patients who are receiving any other investigational agents

          -  Patients with known brain metastases should be excluded from this clinical trial

          -  History of allergic reactions attributed to compounds of similar chemical or
             biological composition to temsirolimus or lenalidomide used in study

          -  Patients requiring active anti-retroviral therapy for HIV are excluded

          -  No &quot;currently active&quot; second malignancy, other than non-melanoma skin cancers;
             patients are not considered to have a &quot;currently active&quot; second malignancy if they
             have completed anti-cancer therapy and are considered by their physicians to be at
             less than 30% risk of relapse

          -  No history (within 3 months of study entry) of deep venous thrombosis/pulmonary
             embolism (DVT/PE); patients with a distant history (greater than 3 months before study
             entry) of DVT/PE are eligible, but should receive prophylactic aspirin or low
             molecular weight heparin

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Patients with relapsed/refractory DLBCL or HL who are eligible and willing to undergo
             potentially curative stem cell transplant

          -  Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) are
             excluded

          -  No corticosteroids within 14 days prior to study, except for maintenance therapy for a
             non-malignant disease; maintenance therapy dose may not exceed 10 mg/day prednisone or
             equivalent; any patient on steroid therapy must receive thromboembolic prophylaxis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonali Smith</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hospital</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Illinois CancerCare-Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Illinois Hematology Oncology Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Illinois University School of Medicine</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology Inc-Parkview</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University/Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland/Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 25, 2010</study_first_submitted>
  <study_first_submitted_qc>February 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <results_first_submitted>August 15, 2019</results_first_submitted>
  <results_first_submitted_qc>September 24, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 16, 2019</results_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 8, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT01076543/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase I, All Histologies, Lenalidomide 15 mg</title>
          <description>Patients receive lenalidomide 15 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="P2">
          <title>Phase I, All Histologies, Lenalidomide 20 mg</title>
          <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="P3">
          <title>Phase I, All Histologies, Lenalidomide 25 mg</title>
          <description>Patients receive lenalidomide 25 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="P4">
          <title>Phase II, Diffuse Large B-Cell Subtype</title>
          <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="P5">
          <title>Phase II, Follicular Subtype</title>
          <description>Patients receive lenalidomide 20mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="P6">
          <title>Phase II, Lymphoma NOS</title>
          <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="39"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I, All Histologies, Lenalidomide 15 mg</title>
          <description>Patients receive lenalidomide 15 mg PO on days 1-21 and25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="B2">
          <title>Phase I, All Histologies, Lenalidomide 20 mg</title>
          <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="B3">
          <title>Phase I, All Histologies, Lenalidomide 25 mg</title>
          <description>Patients receive lenalidomide 25 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="B4">
          <title>Phase II, Diffuse Large B-Cell Subtype</title>
          <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="B5">
          <title>Phase II, Follicular Subtype</title>
          <description>Patients receive lenalidomide 20mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="B6">
          <title>Phase II, Lymphoma NOS</title>
          <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="39"/>
            <count group_id="B5" value="15"/>
            <count group_id="B6" value="39"/>
            <count group_id="B7" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" lower_limit="41" upper_limit="73"/>
                    <measurement group_id="B2" value="65.2" lower_limit="56" upper_limit="77"/>
                    <measurement group_id="B3" value="65.3" lower_limit="41" upper_limit="80"/>
                    <measurement group_id="B4" value="64.1" lower_limit="25" upper_limit="78"/>
                    <measurement group_id="B5" value="63.3" lower_limit="43" upper_limit="76"/>
                    <measurement group_id="B6" value="47.4" lower_limit="23" upper_limit="72"/>
                    <measurement group_id="B7" value="57.9" lower_limit="23" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Dose-limiting Toxicity (DLT), Phase I Patients Only</title>
        <description>Incidence of dose-limiting toxicity (DLT) defined as any grade 3 or 4 adverse events as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)</description>
        <time_frame>28 days</time_frame>
        <population>Only phase I patients were assessed for dose-limiting toxicity per 3+3 dose-escalation design to determine the maximum tolerated dose (MTD).</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I, All Histologies, Lenalidomide 15 mg</title>
            <description>Patients receive lenalidomide 15 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O2">
            <title>Phase I, All Histologies, Lenalidomide 20 mg</title>
            <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O3">
            <title>Phase I, All Histologies, Lenalidomide 25 mg</title>
            <description>Patients receive lenalidomide 25 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O4">
            <title>Phase II, Diffuse Large B-Cell Subtype</title>
            <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O5">
            <title>Phase II, Follicular Subtype</title>
            <description>Patients receive lenalidomide 20mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O6">
            <title>Phase II, Lymphoma NOS</title>
            <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Dose-limiting Toxicity (DLT), Phase I Patients Only</title>
          <description>Incidence of dose-limiting toxicity (DLT) defined as any grade 3 or 4 adverse events as graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)</description>
          <population>Only phase I patients were assessed for dose-limiting toxicity per 3+3 dose-escalation design to determine the maximum tolerated dose (MTD).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Maximum tolerated dose in mg</param_type>
            <param_value>20</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>The maximum tolerated dose (MTD) was determined using the traditional &quot;3+3&quot; design and was the maximum dose level such that less than 33% of the patients (i.e, &lt;1 of 3 or &lt;2 of 6) experience dose-limiting toxicity.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Complete Response (Phase II)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions;</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Only phase II patients were assessed for complete response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I, All Histologies, Lenalidomide 15 mg</title>
            <description>Patients receive lenalidomide 15 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O2">
            <title>Phase I, All Histologies, Lenalidomide 20 mg</title>
            <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O3">
            <title>Phase I, All Histologies, Lenalidomide 25 mg</title>
            <description>Patients receive lenalidomide 25 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O4">
            <title>Phase II, Diffuse Large B-Cell Subtype</title>
            <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O5">
            <title>Phase II, Follicular Subtype</title>
            <description>Patients receive lenalidomide 20mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O6">
            <title>Phase II, Lymphoma NOS</title>
            <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Response (Phase II)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions;</description>
          <population>Only phase II patients were assessed for complete response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (Phase II)</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Only phase II patients were assessed for overall response.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I, All Histologies, Lenalidomide 15 mg</title>
            <description>Patients receive lenalidomide 15 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O2">
            <title>Phase I, All Histologies, Lenalidomide 20 mg</title>
            <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O3">
            <title>Phase I, All Histologies, Lenalidomide 25 mg</title>
            <description>Patients receive lenalidomide 25 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O4">
            <title>Phase II, Diffuse Large B-Cell Subtype</title>
            <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O5">
            <title>Phase II, Follicular Subtype</title>
            <description>Patients receive lenalidomide 20mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O6">
            <title>Phase II, Lymphoma NOS</title>
            <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (Phase II)</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <population>Only phase II patients were assessed for overall response.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Two-stage, minimax design was used to test the null hypothesis that the overall response rate was 30% vs. a 50% alternative.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&gt;0.10</p_value>
            <method>Binomial exact test</method>
            <method_desc>The number of responders required to reject the null hypothesis was 16 or more.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Two-stage, minimax design was used to test the null hypothesis that the overall response rate was 50% vs. 70% alternative.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <other_analysis_desc>The follicular subgroup did not reach its accrual goal and was closed.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Two-stage, minimax design was used to test the null hypothesis that the overall response rate was 30% vs. a 50% alternative.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.10</p_value>
            <method>Binomial exact test.</method>
            <method_desc>The number of responders required to reject the null hypothesis was 16 or more.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS) (Phase II)</title>
        <description>Kaplan-Meier curves will be generated for PFS stratified by histology; median PFS times will be determined and 90% confidence intervals derived as described in Brookmeyer and Crowley.</description>
        <time_frame>Time from study entry until disease progression or death from any cause, assessed up to 5 years</time_frame>
        <population>Note: Only phase II patients were followed for progression-free survival.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I, All Histologies, Lenalidomide 15 mg</title>
            <description>Patients receive lenalidomide 15 mg PO on days 1-21 and25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O2">
            <title>Phase I, All Histologies, Lenalidomide 20 mg</title>
            <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O3">
            <title>Phase I, All Histologies, Lenalidomide 25 mg</title>
            <description>Patients receive lenalidomide 25 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O4">
            <title>Phase II, Diffuse Large B-Cell Subtype</title>
            <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O5">
            <title>Phase II, Follicular Subtype</title>
            <description>Patients receive lenalidomide 20mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O6">
            <title>Phase II, Lymphoma NOS</title>
            <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) (Phase II)</title>
          <description>Kaplan-Meier curves will be generated for PFS stratified by histology; median PFS times will be determined and 90% confidence intervals derived as described in Brookmeyer and Crowley.</description>
          <population>Note: Only phase II patients were followed for progression-free survival.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="7.0" lower_limit="3.5" upper_limit="8.0"/>
                    <measurement group_id="O5" value="27.7" lower_limit="6.5" upper_limit="35.8"/>
                    <measurement group_id="O6" value="7.0" lower_limit="4.6" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) (Phase II)</title>
        <description>Kaplan-Meier curves will be generated for OS stratified by histology; median OS times will be determined and 90% confidence intervals derived as described in Brookmeyer and Crowley.</description>
        <time_frame>Time from study entry until death from any cause, assessed up to 6 years</time_frame>
        <population>Only phase II patients were followed for overall survival.
Note:999999 for the upper confidence interval of the median for the follicular subtype means &quot;not estimable.&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>Phase I, All Histologies, Lenalidomide 15 mg</title>
            <description>Patients receive lenalidomide 15 mg PO on days 1-21 and25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O2">
            <title>Phase I, All Histologies, Lenalidomide 20 mg</title>
            <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O3">
            <title>Phase I, All Histologies, Lenalidomide 25 mg</title>
            <description>Patients receive lenalidomide 25 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O4">
            <title>Phase II, Diffuse Large B-Cell Subtype</title>
            <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O5">
            <title>Phase II, Follicular Subtype</title>
            <description>Patients receive lenalidomide 20mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
          <group group_id="O6">
            <title>Phase II, Lymphoma NOS</title>
            <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) (Phase II)</title>
          <description>Kaplan-Meier curves will be generated for OS stratified by histology; median OS times will be determined and 90% confidence intervals derived as described in Brookmeyer and Crowley.</description>
          <population>Only phase II patients were followed for overall survival.
Note:999999 for the upper confidence interval of the median for the follicular subtype means &quot;not estimable.&quot;</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="15"/>
                <count group_id="O6" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="9.1" lower_limit="6.0" upper_limit="16.0"/>
                    <measurement group_id="O5" value="35.8" lower_limit="18.8" upper_limit="NA">The upper confidence limit could not be determined due to the censoring.</measurement>
                    <measurement group_id="O6" value="25.5" lower_limit="10.8" upper_limit="60.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Mortality collected up to 6 years; all other AEs collected up to 2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Phase I, All Histologies, Lenalidomide 15 mg</title>
          <description>Patients receive lenalidomide 15 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="E2">
          <title>Phase I, All Histologies, Lenalidomide 20 mg</title>
          <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="E3">
          <title>Phase I, All Histologies, Lenalidomide 25 mg</title>
          <description>Patients receive lenalidomide 25 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="E4">
          <title>Phase II, Diffuse Large B-Cell Subtype</title>
          <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="E5">
          <title>Phase II, Follicular Subtype</title>
          <description>Patients receive lenalidomide 20mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
        <group group_id="E6">
          <title>Phase II, Lymphoma NOS</title>
          <description>Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE 4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Colonic perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Colonic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Stomatitis/Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vascular access complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant, and unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mood alteration - depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous disorders - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vascular disorders - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE 4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>INR increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothryoidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dysphagia, esophagitis, odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oral dysesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rectal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tooth development disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neck edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Edema face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Edema trunk</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Serum sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gum infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Stomatitis/pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Papulopustular rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline aminotransferase increase</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="31" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="26" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="34" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>CD4 lymphocytes decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Investigations - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="33" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="30" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased lumbar spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neuropathy - motor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mood alteration - depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nail discoloration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash/dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nail ridging</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nail loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Scalp pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Superficial thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sonali Smith, Professor of Medicine</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-834-2895</phone>
      <email>smsmith@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

